Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition

Improved prognosis for triple-negative breast cancer (TNBC) has currently plateaued and the development of novel therapeutic strategies is required. Therefore, we aimed to explore the anti-tumor effect of eribulin and paclitaxel combination therapy for TNBC. The effect of eribulin and paclitaxel in...

Descripción completa

Detalles Bibliográficos
Autores principales: Oba, Takaaki, Ito, Ken-Ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955406/
https://www.ncbi.nlm.nih.gov/pubmed/29796167
http://dx.doi.org/10.18632/oncotarget.25184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955406/
https://www.ncbi.nlm.nih.gov/pubmed/29796167
http://dx.doi.org/10.18632/oncotarget.25184

Ejemplares similares